Alkem Laboratories appointed Amrut Naik as its new Chief Executive Officer, effective November 11. The board approved this move on November 3 following a committee recommendation. Naik brings over 25 years of pharmaceutical industry experience to the role, having previously held leadership positions at Zydus Group and Lupin Pharmaceuticals.
Alkem Laboratories has appointed Amrut Naik as its Chief Executive Officer (CEO) and Key Managerial Personnel, with effect from November 11, 2026.
A CNBC-TV18 Newsbreak on the appointment has now been confirmed as Alkem's board of directors approved the appointment at a meeting held on November 3, following a recommendation from its Nomination and Remuneration Committee.
Naik brings over 25 years of experience in the pharmaceutical industry, having held leadership positions at Zydus Group and Lupin Pharmaceuticals, among others. He most recently served as President of Zydus Group, a position he held from July 2016 to November 2026.
Naik's leadership journey
Before joining Alkem, Naik spent over 10 years at Zydus Group as President. Prior to that, he was Managing Director of Lupin Pharmaceuticals in Mexico from July 2013 to July 2016.
He also served as Senior Vice President at Lupin between July 2008 and June 2013, where he led the company's business in emerging markets and worked on business acquisitions, joint ventures and strategic alliances across multiple continents.
Naik has over 15 years of experience in chief executive-level roles, overseeing business development, sales and marketing, technical operations and mergers and acquisitions (M&A). His professional profile also states that he has closed five cross-border deals and established two joint ventures.
His experience spans branded formulations, generics, active pharmaceutical ingredients (APIs), biologics, vaccines, specialty products and innovation-led portfolios.
His industry roles and academic background
Beyond his corporate roles, Naik served as Chairperson of the Federation of Indian Chambers of Commerce and Industry (FICCI) Regional Council between 2023 and 2025. He is also a member of FICCI's National Executive Committee.
Naik holds a PhD (Tech) in Pharmacology, a Master's degree in Pharmaceutical Science and a Bachelor's degree in Pharmaceutical Science.
According to Alkem's filing, his appointment will continue for the duration of his employment with the company.